ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Roche has stopped a Phase III trial of dalcetrapib, a compound that raises levels of high-density lipoprotein, or “good” cholesterol, by blocking cholesteryl ester transfer protein (CETP). Dalcetrapib, which Roche had hoped would have blockbuster sales—over $1 billion per year—failed to show signs of meaningful benefit in patients with heart disease. Dalcetrapib inhibits the same target as Pfizer’s torcetrapib, which was pulled from development in 2006 after safety problems cropped up in a late-stage trial. The Roche drug disappointment raises concerns for the future of other CETP inhibitors being developed by Merck & Co. and Eli Lilly & Co.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X